|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.920 CNY | +0.87% |
|
+0.73% | -4.16% |
| 07-09 | Shanghai RAAS Gets China Clinical Trial Approval for Blood Clot Drug | MT |
| 06-20 | RAAS Blood Products Completes Full Acquisition of Nanyue Biopharmaceutical | MT |
| Capitalization | 45.7B 6.37B 5.44B 5.07B 4.69B 8.72B 546B 9.75B 60.65B 23.08B 255B 23.88B 23.38B 933B | P/E ratio 2025 * |
19.1x | P/E ratio 2026 * | 17.4x |
|---|---|---|---|---|---|
| Enterprise value | 39.55B 5.51B 4.71B 4.38B 4.06B 7.55B 472B 8.44B 52.48B 19.97B 221B 20.66B 20.23B 807B | EV / Sales 2025 * |
4.47x | EV / Sales 2026 * | 4.15x |
| Free-Float |
69.51% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
More news
| 1 day | +0.87% | ||
| 1 week | +0.73% | ||
| Current month | +0.73% | ||
| 1 month | -1.14% | ||
| 3 months | -0.57% | ||
| 6 months | +2.82% | ||
| Current year | -4.16% |
| 1 week | 6.83 |  | 7.03 |
| 1 month | 6.76 | | 7.04 |
| Current year | 6.5 | | 7.3 |
| 1 year | 6.42 | | 8.68 |
| 3 years | 5.17 | | 8.68 |
| 5 years | 4.98 | | 11.16 |
| 10 years | 4.98 | | 26.67 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jun Xu
CEO | Chief Executive Officer | 61 | - |
Le Qi Chen
DFI | Director of Finance/CFO | 38 | 25/10/2021 |
Hong Qiu
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Wei Bing Hu
BRD | Director/Board Member | 61 | 20/05/2020 |
Li Xia Tan
CHM | Chairman | 55 | 29/07/2024 |
Jun Xu
CHM | Chairman | 61 | - |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0.69% | 0 M€ | -19.71% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.87% | +0.73% | -8.47% | +14.38% | 6.32B | ||
| -0.47% | +1.18% | -18.74% | -15.76% | 77.69B | ||
| +0.88% | +3.30% | -47.49% | -11.10% | 57.88B | ||
| +0.49% | +1.80% | +28.54% | +24.30% | 52.56B | ||
| +0.12% | +2.07% | +19.26% | +98.16% | 37.85B | ||
| -1.07% | +2.27% | -41.68% | -39.20% | 19.7B | ||
| -0.12% | +4.91% | +117.59% | +123.51% | 17.93B | ||
| +1.07% | +13.69% | +55.41% | +695.31% | 16.32B | ||
| -0.04% | -.--% | +84.28% | +129.06% | 14.02B | ||
| +1.55% | -0.01% | +18.14% | -14.61% | 13.1B | ||
| Average | +0.33% | +1.95% | +20.69% | +100.40% | 31.34B | |
| Weighted average by Cap. | +0.21% | +1.88% | +5.05% | +56.25% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 8.85B 1.23B 1.05B 981M 907M 1.69B 106B 1.89B 11.74B 4.47B 49.35B 4.62B 4.53B 181B | 9.36B 1.3B 1.11B 1.04B 960M 1.79B 112B 2B 12.42B 4.73B 52.21B 4.89B 4.79B 191B |
| Net income | 2.35B 327M 280M 261M 241M 449M 28.07B 502M 3.12B 1.19B 13.11B 1.23B 1.2B 47.99B | 2.64B 368M 314M 293M 271M 504M 31.51B 563M 3.5B 1.33B 14.72B 1.38B 1.35B 53.86B |
| Net Debt | -6.15B -857M -732M -682M -631M -1.17B -73.48B -1.31B -8.17B -3.11B -34.33B -3.22B -3.15B -126B | -6.84B -953M -814M -759M -702M -1.31B -81.71B -1.46B -9.08B -3.46B -38.17B -3.58B -3.5B -140B |
More financial data
* Estimated data
Employees
3,350
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/07/25 | 6.920 ¥ | +0.87% | 73,373,900 |
| 08/07/25 | 6.860 ¥ | +0.29% | 28,211,000 |
| 07/07/25 | 6.840 ¥ | -0.15% | 22,243,180 |
| 04/07/25 | 6.850 ¥ | -0.29% | 25,489,500 |
| 03/07/25 | 6.870 ¥ | +0.29% | 36,107,420 |
End-of-day quote Shenzhen S.E., July 08, 2025
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
6.920CNY
Average target price
6.200CNY
Spread / Average Target
-10.40%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 002252 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition